Impact of Spiroware re-analysis method on multiple-breath washout outcomes in children with cystic fibrosis
- PMID: 35232654
- DOI: 10.1016/j.jcf.2022.02.013
Impact of Spiroware re-analysis method on multiple-breath washout outcomes in children with cystic fibrosis
Conflict of interest statement
Declaration of Competing Interest All authors are in regular contact with manufacturers of MBW devices. The authors declare no conflict of interest. Prof. Latzin: personal fees from Vertex, Novartis, Roche, Polyphor, Vifor, Gilead, Schwabe, Zambon, Santhera, grants from Vertex, all outside this work. All other authors declare no conflicts of interest.
Comment in
-
Re: Impact of spiroware re-analysis method on multiple-breath washout outcomes in children with cystic fibrosis; M.A. Oestreich, F. Wyler, P. Latzin et al.J Cyst Fibros. 2022 May;21(3):e210-e211. doi: 10.1016/j.jcf.2022.04.001. Epub 2022 Apr 9. J Cyst Fibros. 2022. PMID: 35414443 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
